Use this URL to cite or link to this record in EThOS:
Title: The role of the gene SERPINH1 as a pharmacogenetic biomarker for choroidal neovascularization (CNV) responses to anti vascular endothelial growth factor (VEGF) treatment in clinical practice
Author: Pierce, Charles
ISNI:       0000 0004 6500 6032
Awarding Body: University of Southampton
Current Institution: University of Southampton
Date of Award: 2015
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Age related macular degeneration is the commonest cause of blindness in the western world and current treatment regimens represent a significant output for national health services. The disease process is multifactorial in origin and has a variable progression and response to current methods of treatment. A targeted approach with individualized therapy based on recognized biomarkers to predict disease outcome would be the ideal treatment modality. We plan to investigate the role of genes known to influence the progression of early AMD to the advanced stage (wet AMD) with emphasis on genes involved in complement regulation (SERPING1, CFB, CFI, CFH, C2 and C3). The investigation will also encompass other genotypes involved in AMD pathogenesis. Polymorphic variations in the gene SERPING1, which codes for complement 1 inhibitor (C1Inh), have been previously implicated in AMD pathogenesis. Many clinical trials involving complement antagonists are currently proceeding at various stages of development. We plan to investigate the role of C1Inh in AMD development and explore its potential as a therapeutic agent, utilising Ccl2-/-/Cx3cr1-/- (in the presence of an rd8 mutation in the Crb1 gene) and wild type C57BL/6 mice. In the neurodegenerative condition Alzheimer’s disease, acute or chronic and chronic systemic inflammation have been associated with progression of symptoms. Both chronic and acute inflammation have been implicated in choroidal angiogenesis and subsequent AMD development. We hypothesised that systemic inflammation may alter the response of AMD to the anti-vascular endothelial growth factor (VEGF) agent ranibizumab. Inflammatory markers may therefore offer an objective indicator of future treatment response. These experiments will provide a comprehensive analysis of prognostic indicators for AMD and investigate a potentially new therapeutic agent.
Supervisor: Lotery, Andrew Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID:  DOI: Not available